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Introduction
 Perinatal mood disorders (PMD) are the most 
common complication of childbirth and have significant 
repercussions, in terms of morbidity and mortality, on 
the mother, infant, and family.1-9 Postpartum depres-
sion has a prevalence of 10% to 15% and is the most 
frequent type of PMD.1,7 Postpartum psychosis is a rare 
but severe form of PMD that can result in tragic conse-
quences, including suicide and infanticide,10,11 and has 
been closely associated with bipolar disorder (BPD).12 
PMD-related suicide accounts for ~20% of all postpar-
tum deaths, making PMD a leading cause of maternal 
perinatal mortality.6,13
 The effects of untreated PMD during pregnancy in-
clude delayed prenatal growth, higher rates of prematu-
rity, and low birth weight.2 Moreover, antenatal depres-
sion is one of the greatest risk factors for postpartum 
depression, and therefore psychiatric illness during 
pregnancy must be adequately treated to prevent sig-
nificant postpartum adverse outcomes. PMD is also 
associated with reduced maternal sensitivity,14 which 
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The perinatal period is a time of high risk for women 
with unipolar and bipolar mood disorders. We discuss 
treatment considerations for perinatal mood disorders, 
including unipolar and bipolar depression as well as 
postpartum psychosis. We further explore the unique is-
sues faced by women and their families across the full 
trajectory of the perinatal period from preconception 
planning through pregnancy and following childbirth. 
Treatment of perinatal mood disorders requires a col-
laborative care approach between obstetrics practi-
tioners and mental health providers, to ensure that a 
thoughtful risk:benefit analysis is conducted. It is vital 
to consider the risks of the underlying illness versus risks 
of medication exposure during pregnancy or lactation. 
When considering medication treatment, attention 
must be paid to prior medication trials that were most 
efficacious and best tolerated. Lastly, it is important to 
assess the impact of individual psychosocial stressors and 
lifestyle factors on treatment response.          
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can adversely affect emotional regulation and attach-
ment.15,16 
 Women with histories of both unipolar and bipolar 
mood disorders are at increased risk for exacerbation 
or recurrence during the vulnerable perinatal period. 
Therefore, in women with histories of affective illness, 
careful planning and monitoring by a skilled perina-
tal mental health specialist in collaboration with the 
obstetrics team should begin prior to pregnancy (pre-
conception) and continue through the pregnancy and 
postpartum period. In addition, for many women, the 
perinatal period serves as the trigger for fi rst onset of 
psychiatric illness. There are many reported risk factors 
for perinatal psychiatric illness, but previous histories of 
PMD or prior episodes of non-perinatal major depres-
sion or BPD appear to confer the greatest risks.4,17-19 In 
addition, parity status, marital confl ict, perceived lack of 
partner support, stressful life events, unplanned preg-
nancy, and adverse pregnancy/birth outcomes have also 
been reported.2 
 In this paper, we will discuss treatment consid-
erations of perinatal mood disorders, including uni-
polar and bipolar depression, as well as postpartum 
psychosis. We will explore the unique issues faced by 
women and their families across the full trajectory of 
the perinatal period from the time of preconception 
planning, through pregnancy, and following childbirth 
(Figure 1).
Unipolar major depression
Epidemiology, defi nition of the disorder, and clinical 
characteristics
Major depression occurring in the perinatal period is 
often described as antenatal depression if onset is dur-
ing pregnancy, or postpartum depression if onset occurs 
following childbirth. However, there is some debate in 
the fi eld about the diagnostic criteria based on timing 
of onset of PMDs. Consequently, this has led to recent 
changes in diagnostic criteria of postpartum depression 
by the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM)-5, resulting in an expanded defi nition that 
includes onset of symptoms during pregnancy as well as 
postpartum and a consequent change in terminology to 
“peripartum” onset.20 In contrast, in the International 
Classifi cation of Diseases (ICD)-10, postpartum onset is 
considered to be within 6 weeks after childbirth with no 
specifi c recognition of episodes in pregnancy.21 
 The clinical presentation of perinatal depression is 
often characterized by mood and anxiety symptoms 
that cause signifi cant suffering to the woman and her 
family.22-24 Women with perinatal depression commonly 
report low mood, sadness, irritability, impaired concen-
tration, and feeling overwhelmed.25 However, anxiety 
or agitation is often a distinctive feature of perinatal 
depression and can manifest as ruminating and obses-
sional thoughts, often about the pregnancy or the in-
fant.23,26 Importantly, most women with perinatal mood 
symptoms report feelings of guilt about not being able 
to enjoy the baby.27,28
Treatment of unipolar depression in the perinatal 
period
Preconception
For women with a history of a unipolar depressive dis-
order, the primary goal of the preconception period 
is to achieve stability in mood and review the current 
treatment plan to assess safety during pregnancy. For 
some women, it may make sense to try to discontinue 
a psychotropic medication. For others, this would be a 
very unsafe choice and put the woman’s mental health 
at risk. Thoughtful and careful consideration of the 
risk:benefi t ratio is warranted, including assessment of 















 Figure 1.  Conceptual model of treatment considerations across the 
perinatal period.
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prior response to treatment, past attempts to discontin-
ue medication treatment, and risk of exposure to psy-
chotropic medications during pregnancy. In high-risk 
women, a prudent approach to the preconception pe-
riod involves assembling a team of specialized perinatal 
providers including obstetricians, psychiatrists, psychol-
ogists, and others to support the woman through preg-
nancy and the postpartum period and assist in judicious 
decision making that will lead to the best outcomes for 
both mother and infant. We provide two case reports 
(Box 1 and Box 2) to illustrate the decision-making pro-
cess.
Pregnancy
For pregnant women with mild-to-moderate depressive 
illness, psychological and/or behavioral therapies are 
indicated as first-line treatment options.28,29 There exists 
a robust evidence base on the efficacy of a wide range 
of psychological interventions including, but not limited 
to, interpersonal psychotherapy (IPT),30-33 partner-as-
sisted IPT,33 cognitive behavioral therapy,34,35 and group 
psychoeducation.36,37 It is important to tailor the type of 
therapeutic modality to the primary presenting symp-
toms of the patient. For example, women who report 
significant psychosocial issues may be best served by 
seeking IPT, which is a time-limited, problem-focused 
therapy that interprets depression as medical illness oc-
curring within a social context.38 In contrast, a women 
who has experienced a prior negative or traumatic birth 
experience as a trigger for onset of symptoms will likely 
experience the most benefit from a psychotherapy that 
integrates trauma recovery work.
 For more severe depressive and anxiety symptoms, 
pharmacotherapy is considered an appropriate and ef-
ficacious treatment option.29,39 Antidepressant medica-
tion (ADM) has quickly become a common treatment 
for perinatal depression. The current practice in many 
settings is that ADM is the most effective way to treat 
perinatal depression, and, while perhaps not as accept-
able due to fetal exposure, it may be more accessible 
to patients than lengthy psychosocial interventions.40 In 
the US, prenatal ADM use in the last 15 years has more 
than doubled, with approximately 13% of pregnancies 
in the year 2003 exposed to ADM, compared with 6% 
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Box 1.  Case report #1. Box 2.  Case report #2.
Ms T is a 32-year-old married woman with a history 
of BPD type I, currently stable on lithium, who pre-
sents for a preconception evaluation and states she is 
hoping to conceive in the next 6 months and wants to 
discuss medication management during the perinatal 
period. Ms T reports she has been stable on lithium 
for many years. Her first episode of mania was in her 
early 20s, at which time she experienced symptoms 
of elevated mood, grandiosity, and psychosis. She 
was hospitalized at that time and lithium therapy 
was initiated with good results. A few years later she 
attempted to discontinue lithium, and suffered a re-
lapse of a manic episode with psychosis. She is fear-
ful of discontinuing lithium during her pregnancy 
but is concerned about the risk of lithium exposure 
to the fetus. Her husband, who accompanies his wife 
to the appointment, is also worried about the risks to 
his wife and the fetus.
 A careful discussion of the risks and benefits of 
psychotropic exposure during pregnancy versus the 
risk of discontinuation is discussed with the patient 
and her husband. Given the patient’s history of suf-
fering a relapse of mania soon after her lithium was 
discontinued in the past, the patient and her husband 
elect to continue lithium therapy during the pre-
gnancy. 
Ms D is a 29-year-old woman with a history of an-
xiety and depression who presents for evaluation at 
6 weeks of pregnancy. She reports she has taken an 
antidepressant (SSRI) at a low dose for the past 5 
years with good results. She has not tried to discon-
tinue the medication. She reports that at the time of 
initiation with the antidepressant, she had multiple 
significant stressors in her life and had ruminating 
thoughts, low mood, anhedonia, and insomnia. She 
denies ever having suicidal thoughts. Ms D now 
reports she is feeling well and has good psychoso-
cial support. She is concerned about antidepressant 
exposure during pregnancy and states that worrying 
about taking the antidepressant is causing her signi-
ficant anxiety. Her partner is pushing the patient to 
discontinue the antidepressant. 
 After a careful discussion of risks and benefits, Ms 
D decides to gradually taper off her antidepressant 
with careful monitoring during the pregnancy. 
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in 1999.41 A new epidemiological report of ADM use 
in US Medicaid-eligible women (2000-2007) reported 
that nearly one in twelve women used an ADM dur-
ing pregnancy. In Europe, the rate of prenatal ADM 
use has also increased, but at a lower rate compared 
with the US. A Danish study documents that the rate of 
ADM exposure increased from 0.2% in 1997 to 3.2% in 
2010.42 
 Despite the increased use of ADM in pregnancy, 
the literature on overall safety of ADM exposure in 
pregnancy based on observational studies, drug regis-
try analyses, and case series reports is conflicting. This is 
largely due to the challenge of controlling for potential 
confounders including the underlying pathophysiology 
of the mood disorder and/or lifestyle factors (ie, diet, 
obesity, and substance use) that are more prevalent in 
women with mood disorders.43 Accordingly, ongoing 
concerns about fetal drug exposure are constantly be-
ing raised, and this has been an intense area of study 
resulting in many published reports and papers over the 
past decade.44-46 The focus of this line of inquiry is on 
the potential associations/interactions between ADM, 
depression, and adverse fetal outcomes (preterm birth, 
primary persistent pulmonary hypertension of the new-
born, risk of autism, ADHD, and cardiac effects) as 
well as the lack of information regarding comparative 
treatment efficacy. The overall result is that women and 
their clinicians are forced to make difficult decisions 
regarding treatment in the face of inconsistent litera-
ture. These controversies can discourage women from 
seeking antidepressant treatment, even though declin-
ing treatment may pose significant risks to the fetus and 
their own mental health.47-50 Moreover, many women 
will receive inadequate doses of ADM during preg-
nancy because of fear that adverse events may be dose-
related.51,52 This practice results in the potential double 
exposure to both the ADM and the ongoing depressed 
mood. 
 Recently there have been a number of large sys-
tematic reviews and meta-analyses demonstrating the 
absolute risks associated with antidepressant exposure 
during pregnancy to be small, although certainly pres-
ent.48,52,53 There is evidence for the efficacy of both new-
er antidepressants (selective serotonin reuptake inhibi-
tors—SSRIs) and older tricyclic antidepressants in the 
treatment of perinatal depression and anxiety.54,55 The 
benzodiazepines are also commonly used for treatment 
of anxiety during pregnancy and lactation and are now 
generally considered safe in the perinatal period if in-
dicated.56-60 This is in contrast to the early case-control 
studies that reported that maternal benzodiazepine 
exposure increased the risk of fetal cleft lip and cleft 
palate, primarily with diazepam exposure.61 Multiple 
subsequent studies and meta-analyses have not found 
an association, but some concern remains and judicious 
use is advised.56 In sum, the decision to treat with an 
antidepressant medication during pregnancy may be a 
difficult choice for the mother, her partner, and the phy-
sician. The literature remains conflicted, and ultimately, 
treatment decisions regarding how best to treat depres-
sion during pregnancy must be made on an individual 
basis, with thoughtful evaluation of decision risks to 
mother and infant.62
 Finally, it is important to state that the stigma asso-
ciated with mental illness becomes highly exacerbated 
during the perinatal period. Consequently, pregnant 
women may be faced with significant stigma and ex-
perience shame if they decide to continue taking their 
antidepressant or other psychotropic medication dur-
ing pregnancy in order to maintain their own mental 
health. This is a situation that they would likely not en-
counter if they were seeking treatment for a different 
medical illness, such as diabetes or hypertension.51
 Because of the controversies surrounding antide-
pressant use during pregnancy, there is a need for oth-
er evidence-based treatment modalities for perinatal 
depression and anxiety. Examples include hormonal 
therapy,63 such as the use of the estrogen patch in the 
prevention and treatment of PMD, bright-light therapy 
in antenatal depression,64-66 and the administration of 
repetitive transcranial magnetic stimulation (rTMS) 
during pregnancy67,68 and the postpartum period.69,70 
Although these modalities are potentially interesting 
treatment options for the perinatal period, the evidence 
base is currently limited, and further work is needed to 
build upon initial findings.
The postpartum period
The postpartum period is one of the times of highest risk 
for onset of a depressive episode.71 While some women 
experience onset of mood symptoms during pregnan-
cy (often in the third trimester), others will notice an 
acute worsening of symptoms in the first weeks post-
partum. Symptoms that persist and are severe enough 
to impair functioning require evaluation and treatment. 
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The treatment modalities discussed earlier (antidepres-
sant medications and psychotherapies) all demonstrate 
efficacy in the postpartum period. However, there are 
three additional relevant issues that are unique to the 
postpartum time interval: the first is lactation, the sec-
ond is preservation of sleep, and the third is the impact 
of postpartum depression on fathers.
Lactation
Approximately 77% of mothers in the United States 
and over 80% of women in the UK initiate breastfeed-
ing.72,73 Therefore, given that most women will breast-
feed, a careful assessment of psychotropic use during 
lactation is an important discussion to have with the 
mother who is being treated for a mood disorder.74 The 
SSRIs are generally well tolerated during lactation, but 
two agents in this class may be less desirable because 
of breast milk accumulation: (i) fluoxetine, because it 
has a long half-life75; and (ii) citalopram, because of po-
tentially high breast milk concentration.76 In contrast, 
sertraline has a very favorable profile during lactation, 
with very little to no transmission at doses less than 100 
mg.74,77
 Information about the safety of medications during 
lactation can be easily accessed by both clinicians and 
patients via a number of reliable resources. In general, 
resources maintained by academic centers or govern-
mental agencies provide evidence-based data that is 
most valid. For example, LactMed®, a publicly funded 
database by the US National Library of Medicine, is an 
outstanding online resource that reviews and summa-
rizes safety information about drugs and other chemi-
cals to which breastfeeding mothers may be exposed.78 
It includes information on the levels of these medica-
tions or other substances in breast milk and infant blood 
and the potential adverse effects to the nursing infant. 
All data are extracted from the scientific literature, are 
fully referenced, and undergo a peer review process. 
Other excellent resources include The Breastfeeding/
Human Lactation Center at the University of Roches-
ter in Rochester, New York,79 The Motherisk Program 
in Ontario, Canada80 and The Breastfeeding Network in 
the United Kingdom.81 
 Finally, women with postpartum depression may be 
more likely to experience lactation difficulties.82 This 
can be a source of intense anxiety and distress to the 
mother and requires thoughtful guidance and modifica-
tion of routine breastfeeding recommendations to en-
sure best outcomes. The literature supports the relation 
between postpartum depression and lactation difficul-
ties and/or failure.82 Postpartum depression and anxiety 
have been associated with reduced breastfeeding du-
ration, and neuroendocrine mechanisms may underlie 
this association.83 Additionally, reduced maternal sen-
sitivity in the setting of depressive symptoms may also 
contribute to breastfeeding difficulties.84
Sleep preservation
Disrupted sleep is a ubiquitous phenomenon for wom-
en in the acute postpartum period. The newborn re-
quires frequent feedings and attention, irrespective of 
time of day or night. This results in most mothers feel-
ing exhausted in the early postpartum period.85 Women 
with histories of a mood disorder may be particularly 
vulnerable to the effects of sleep deprivation and con-
sequently, poor postpartum sleep may serve as not only 
a marker of impending depression but also as a con-
tributing cause.86 Reports of disrupted and poor sleep 
during the third trimester of pregnancy are related to 
depressive symptoms in the postnatal period.87 Ad-
ditionally, quality of sleep in late pregnancy may also 
predict the timing and increase the vulnerability for 
recurrence of postpartum depression in women with a 
known history of the disorder.88
Therefore, women with histories of perinatal mood dis-
orders or those with new-onset postpartum depression 
must closely monitor their mood and attempt to pre-
serve blocks of sleep.89,90 This requires the support and 
cooperation of the father, partner, and/or family to take 
shifts with infant feeding to ensure that the mother has 
adequate blocks of sleep. The mother must also be will-
ing to accept that sleep preservation is a critical part 
of the treatment plan. Clinicians treating women with 
postpartum depressive symptoms should monitor sub-
jective sleep quality in the postpartum period in addi-
tion to directly assessing mood symptoms.
Paternal/partner depression in the postpartum period
Social support, and specifically partner support, has 
been observed to be a moderator of depressive symp-
toms during pregnancy and the postpartum.91 Inves-
tigations of postpartum paternal depression report a 
prevalence rate of approximately 10% during the first 
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year postpartum, compared with the period prevalence 
(12 months) rate of 3.8% reported in the general popu-
lation of men.92,93 Although much less research has been 
conducted regarding the infant/child consequences of 
paternal depression, a growing body of evidence is sug-
gesting that infants of depressed fathers demonstrate 
higher levels of distress and greater utilization of com-
munity health care resources, and that detrimental be-
havioral and emotional effects may persist into early 
childhood.94 Therefore, it is important to engage the 
father in the treatment process and to inquire about 
paternal mood and functioning in the context of assess-
ment and treatment of maternal postpartum psychiatric 
illness. 
Bipolar disorder and postpartum psychosis
Epidemiology, definition of the disorder, and clinical 
characteristics
For any woman the transition to parenthood is a po-
tentially difficult time. For women with BPD becoming 
a mother has a number of additional issues that wom-
en, their partners and the clinicians looking after them 
need to consider.95 Women with BPD may experience 
episodes of mood disorder at any time in the perinatal 
period, and there is no evidence to suggest that the risk 
in pregnancy is any lower than at other times.96 Howev-
er, the evidence strongly suggests that the postpartum 
period—particularly the first few postpartum weeks—
are a time of particularly high risk for bipolar women.97 
 Although bipolar women may experience episodes 
of both high and low mood at all levels of severity 
across the whole perinatal period, it is the new onset of 
severe episodes in the immediate postpartum for which 
there is a dramatically increased risk. These later epi-
sodes, traditionally labelled as “postpartum” or “puer-
peral” psychosis (PP), are perhaps of greatest concern 
when managing women with BPD through pregnancy. 
PP most commonly takes the form of mania, severe de-
pression, or a mixed episode with features of both high 
and low mood.98 In addition to the mood component, 
features of psychosis such as delusions and hallucina-
tions are common, and women may also demonstrate 
a marked confusion or perplexity.98 The majority of 
episodes of PP have their onset within 2 weeks of de-
livery, with one retrospective study finding over 50% of 
symptom onsets occurring on postpartum days 1 to 3.99 
These episodes are characterized by sudden onset with 
a rapid deterioration, and the clinical picture is often 
constantly changing, with wide fluctuations in the inten-
sity of symptoms.98,99 
 Clinical and population registry studies are consis-
tent in finding that bipolar women are at very high risk 
(at least 1 in 5, 20%) of suffering a severe recurrence 
following delivery.19,97,100 If episodes of nonpsychotic 
major depression are also included, women with BPD 
are at an even higher risk (approaching 1 in 2, 50%) of 
experiencing a episode of mood disorder in the post-
partum period.19 It is worth noting, however, that the 
data indicating a very high risk of PP in bipolar women 
is based on women with the more severe, BP I form of 
the illness. There is much less data for women with BP 
II (or other forms of illness on the bipolar spectrum) 
and despite evidence suggesting that perinatal episodes 
are common in women with BP II, the risk of PP is con-
siderably lower.19 It is clear, however, that women who 
have experienced a previous PP are at very high risk 
following subsequent pregnancies, with greater than 1 
in 2 (50%) of deliveries affected.101 Studies have also 
suggested that for women with BPD, a family history of 
PP in first-degree relatives gives a similarly high risk in 
the postpartum period.102,103
 In considering the management of women with 
BPD in the perinatal period we will, as for unipolar dis-
order above, think about issues arising preconception, 
in pregnancy, and in the postpartum. 
Treatment of bipolar disorder in the perinatal period
Preconception 
Pregnancy must be a consideration in the management 
of childbearing-aged women with BPD at all times, not 
just when they present as pregnant or wish to become 
pregnant. For these reasons, international guidance 
recommends that certain medications such as valpro-
ate are best avoided where possible in all women with 
BPD in their reproductive years, and that issues around 
family planning and contraception are an important 
area of management.104-106 In addition to these more 
general considerations, it is important that specific pre-
conception advice is available to women at the point 
they are considering starting or extending their families. 
The issues that need to be covered are likely to depend 
on each woman’s individual history, but the very high 
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risk of a severe postpartum episode will be an impor-
tant consideration. Discussions around medication will 
clearly feature prominently, but other pertinent issues 
can be addressed, such as smoking and nutrition.107
 The risks and benefits of medication will need to be 
considered, and the options set out for each individual 
woman. These will include continuing the current regime, 
stopping some or all medication, or switching to other 
medication if there are options with greater evidence of 
safety in pregnancy. In making these difficult decisions it 
is important to recognize that there are often no right and 
wrong answers, and that it is not simply a case of opting 
for the medication with the greatest evidence of safety 
in pregnancy. Rather, the individual woman’s history of 
response to various medications and the consequences if 
they have previously been stopped should be a key fac-
tor in the decisions made. While it is clear that women 
with a history of BPD or a previous PP are at high risk of 
relapse in the postpartum, it is unclear whether starting 
prophylaxis following delivery is sufficient, or whether 
medication should also be taken during pregnancy. One 
study has suggested that the answer to this question may 
be different depending on whether previous episodes are 
limited to the postpartum or also have occurred indepen-
dent of pregnancies.108 Women with bipolar episodes not 
related to the perinatal period were at high risk in preg-
nancy and the postpartum, whereas in those with a his-
tory of postpartum episodes only, the risk was limited to 
after childbirth.
Pregnancy
Although there are few studies that have addressed the 
efficacy of medication in pregnancy, perhaps reflecting 
the ethical and practical problems of research at this 
time, there is direct evidence on the impact of treat-
ment discontinuation on women with BPD. One study 
reported a doubling of risk of relapse and shorter time 
to relapse in women with BPD who discontinued pro-
phylactic mood stabilisers in pregnancy, even after ad-
justing for confounders such as illness severity.96 This 
emphasizes the potential negative impact from stop-
ping or changing medication in those women who are 
stable on their current regime and highlights the need 
for these risks to weigh heavily in the individual risk 
benefit calculation.
 Despite the postpartum period being a period of 
particularly high risk, women with BPD, particularly 
those who have stopped or changed medication, may 
become ill during pregnancy and should be monitored 
closely throughout this time. Antenatal services should 
identify women with histories that put them at high 
risk, and even if currently well there is a case for them 
to be under the care of mental health services through 
pregnancy and the postpartum. If a detailed care plan 
has not been produced preconception, then it should be 
developed in pregnancy and address not only issues of 
medication but other relevant areas such as maintain-
ing sleep, decreasing general levels of stress, and think-
ing about whether providing help with parenting may 
be appropriate. Other areas to address may be weight 
management, smoking, and domestic violence.95
 Medication is likely to be a key consideration, how-
ever, and an individualized risk:benefit analysis that 
lays out the options available to each woman is need-
ed. Important areas to address include the likelihood 
of relapse in pregnancy and postpartum based on the 
woman’s particular history, influenced by factors such 
as severity and recency of episodes. It is vital that each 
woman’s history of response to current and past medi-
cation is obtained, and this is factored into the decisions 
made. In women presenting with an unplanned preg-
nancy it is important to appreciate that some exposure 
of the fetus will have already occurred and that abrupt 
discontinuation may not be the best option, as a relapse 
in pregnancy can have devastating consequences. We 
summarize the recommendations for treatment consid-
erations in Table 1.
 It is not possible in this paper to give a detailed re-
view of the reproductive safety data for all potential 
medications that women with BPD may be taking. The 
data regarding the use of antidepressants, which are still 
often used in bipolar patients, has been discussed above. 
We will here make some general observations about the 
other main categories of medication used in these pa-
tients. 
 A number of antiepileptic medications are used as 
mood stabilizers, but we have little data on reproductive 
safety from their use in this context. There is no reason 
to believe, however, that the teratogenicity and adverse 
long-term cognitive outcomes associated with valpro-
ate use will not also apply to its use in BPD.104,109,110
 The atypical antipsychotics are increasingly being 
used in bipolar patients, and despite even less data than 
for antiepileptics, a systematic review111 and the largest 
cohort study to date (n>750 exposures)112 do not sug-
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gest that antipsychotics are major teratogens. While the 
traditional antipsychotics are older agents with more 
data available, they are less effective for mood stabili-
zation in BPD and often have less favorable side-effect 
profiles.113 
 A medication which has been used for many decades, 
but for which we still have surprisingly little reproduc-
tive safety data, is lithium. Initial data from the lithium 
baby registry suggested a particular risk of Ebstein’s 
anomaly, but this was subject to the biases of retrospec-
tive reporting.114 A recent systematic review concluded 
that the evidence pointing to lithium as a teratogen is 
weak, but the confidence intervals are wide and the up-
per confidence limit is consistent with a clinically sig-
nificant increase in risk of congenital malformations.115 
It therefore remains difficult to advise women on the 
risk of continuing this medication, which has been in 
use for over half a century. If lithium is continued in 
pregnancy, levels needs to be checked more frequently 
and stopped at the onset of labor, being reinstated fol-
lowing delivery when plasma levels, and electrolyte bal-
ance, can be checked. This is critical given that lithium is 
primarily cleared by the kidneys and excreted in urine. 
Therefore, the tremendous fluctuations in fluid status 
that occur between onset of labor and the acute post-
partum period make it important to carefully monitor 
lithium levels at the time of childbirth.116
The postpartum period
Where possible, as discussed above, women with BPD 
should enter the postpartum period with a clear man-
agement plan to take them through this period of very 
high risk. This ideal may often not be the case, however, 
and, in addition, around half of postpartum psychosis 
episodes are the first manifestation of severe psychiat-
ric disorder. For women who have stopped medication 
because of the pregnancy, consideration can be given 
to restarting the pre-pregnancy medication regime. Al-
though there has not been extensive research in this 
area, studies provide some support for postpartum lithi-
um prophylaxis for those women at high risk based on a 
previous history of BPD or postpartum psychosis.117-119 
There are significant issues with using lithium at this 
time due to the fluid shifts at the time of childbirth and 
concerns about exposure during lactation, and there-
fore atypical antipsychotics are often used but without 
a solid evidence base for this specific indication.120
 Inpatient treatment is usually required for women 





Achieve stability in mood 
prior to conception and re-
view the current treatment 
plan to assess safety during 
pregnancy.
There are evidence-based psychother-
apies that may be a reasonable first 
line option. 
For more severe depressive and 
anxiety symptoms, or based on prior 
history of discontinuation attempts, 
pharmacotherapy is considered an ap-
propriate and efficacious treatment 
option.
The postpartum period is one of the highest 
risk times for onset of a depressive episode. 
Close follow-up and regular monitoring is 
indicated.
Treatment is important and considerations 
of medication exposure during lactation, 
impact of sleep deprivation and partner sup-
port should all be considered.
Bipolar 
disorder
Review risks and benefits 
and consider the options: 
  •  Continue the current 
regime
  •  Stop some or all medica-
tions
  •  Switch to another 
medication if there are 
options with greater 
evidence of safety in 
pregnancy.  
There is direct evidence of a poten-
tial negative impact from stopping 
or changing medication in bipolar 
women who are stable on their cur-
rent regime. 
This highlights the need for these 
risks to weigh heavily in the individu-
al risk:benefit calculation.
Women with bipolar disorder should enter 
the postpartum period with a clear manage-
ment plan to take them through this period 
of very high risk.
Approximately 50% of postpartum psychosis 
episodes are the first manifestation of severe 
psychiatric disorder.
There is evidence for lithium prophylaxis in 
high risk women.
ECT may also be an option to consider in 
bipolar women with severe postpartum 
episodes particularly if there is significant 
suicidal risk.
Table I.  Important treatment considerations across the trajectory of the perinatal period in women with unipolar depression and bipolar disorder.
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postpartum episode in bipolar women, as deteriora-
tion may be rapid and the illness may soon become 
very severe. Medication is the mainstay of manage-
ment in the acute stage, although psychological sup-
port is often required in the process of recovery. Few 
studies focus on pharmacological treatment of PP so 
the decision about treatment follows the same con-
siderations as it would for similar episodes not relat-
ed to childbirth. Factors needing to be considered in-
clude the individual symptoms experienced, the level 
of disturbance and previous response to medications. 
In addition there are specific side effects, such as ex-
cessive sedation, that may be problematic to a new 
mother which may impact on her ability to care for 
her new baby. Electroconvulsive therapy may also 
be an option to consider in bipolar women with se-
vere postpartum episodes particularly if there is sig-
nificant suicidal risk.121 Severe postpartum episodes 
can raise concern over child protection,with a num-
ber of factors influencing risk including the severity 
of psychiatric history, level of functioning, individual 
social circumstances and relationships. In addition, it 
is important to establish the presence of comorbid 
personality disorder or drug and alcohol problems.122 
It is vital to realize, however, that the majority of 
women with BPD, even those who experience severe 
perinatal episodes, do not have long-term problems 
with parenting.
 The short-term prognosis for postpartum psychosis 
and other perinatal episodes in bipolar women is usually 
excellent, although one study reported one in four women 
to still be experiencing ongoing symptoms at 1 year.11
Conclusions
The perinatal period can best be described as a time 
of high risk, with high stakes for women with unipolar 
and bipolar mood disorders. It is crucial that a thought-
ful risk:benefit analysis is conducted regarding the risks 
of the underlying illness versus risks of medication 
exposure during pregnancy or lactation. The clinician 
providing care must carefully consider prior history of 
response and nonresponse to treatment. When consid-
ering medication treatment, particular attention must 
be paid to prior medication trials that were most effica-
cious and best tolerated by the woman. Considerations 
of psychotherapy and other treatment modalities are 
important to include, as is the impact of both the illness 
and treatment modality on patient, infant, and family. 
More research is needed to guide these very difficult 
decisions that women and their clinicians face at a vul-
nerable time.  o
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